Myocarditis cases hit levels two-to-three times higher in people with a second dose of the Moderna COVID-19 vaccine than the Pfizer BioNTech COVID-19 vaccine, researcher shows.
American College of Cardiology released a study last week that showed that males and females between 18 and 39 with the Moderna vaccine had higher rates of pericarditis and myocarditis. However, males ages 18-29 had the highest rates after receiving the second dose of Moderna.
The National Institutes of Health reports patients experience symptoms of chest pain, fever, fatigue, shortness of breath, and a rapid or irregular pulse, heart failure, shock or death.
Researchers pulled data from approximately 3 million people in British Columbia, Canada, and used participants over the age of 18 who were hospitalized for myocarditis, pericarditis, or myopericarditis within